A randomised phase II trial of adaptive image guided standard or dose escalated tumour boost radiotherapy in the treatment of transitional cell carcinoma of the bladder.
Disease sites: Bladder cancer, urological cancers
Treatment modality: Radiotherapy
Status: In follow-up
RAIDER is a phase II, international, parallel cohort, three arm, two stage randomised trial of adaptive tumour focused radiotherapy for bladder cancer. Stage I will investigate the feasibility of dose escalated tumour boost radiotherapy delivery at multiple centres and Stage II will assess long term side effects of this treatment.
At least 240 participants with muscle invasive bladder cancer will be randomised to one of three treatment groups: standard radiotherapy, standard dose tumour focused adaptive radiotherapy and dose escalated tumour boost adaptive radiotherapy. Participants will have daily radiotherapy for 4 or 6 weeks (depending on standard regimen in use at their hospital) and will be followed up after treatment for a minimum of 5 years.
Chief Investigator: Dr Robert Huddart, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust
ICR-CTSU Scientific Lead: Dr Emma Hall
Trial management contact: [email protected]
Sponsor: The Institute of Cancer Research
Funding: Cancer Research UK (CRUK/14/016)
Further information including recruitment progress is available from the UKCRN portfolio
Publications and presentations
Lewis R, Hall E, Griffin C, Hafeez S, Huddart R. Current UK practice in organ sparing treatment of muscle invasive bladder cancer (MIBC) and impact on design of the RAIDER image guided radiotherapy (IGRT) trial. Presented at: 10th National Cancer Research Institute Cancer Conference; 2014 Nov 2-5; Liverpool, UK.